No Data
No Data
Harbin Gloria Pharmaceuticals (002437.SZ): There is not much pressure on the centralized procurement of the company's core products in the second half of the year.
On July 9th, Gelunhui reported that Harbin Gloria Pharmaceuticals (002437.SZ) stated during a recent investor visit to institutions that the company's main products, including Deer Antler Polypeptide Injection, Potassium Chloride Sustained-Release Tablets (Budexiu), and various vitamins (12) for injection, have already been included in centralized procurement. An Nao Wan/Pian does not yet meet the conditions for centralized procurement. In the second half of the year, the company's core products face little pressure from centralized procurement.
Harbin Gloria Pharmaceuticals (002437.SZ): The target audience of potassium chloride sustained-release tablets (Budexiu) is mainly patients with hypokalemia.
Harbin Gloria Pharmaceuticals (002437.SZ) recently stated during a visit with institutional investors that the target audience for its potassium chloride extended-release tablets (Budaxiu) mainly consists of patients with hypokalemia, some with cardiovascular and cerebrovascular diseases, and those who need hydration due to excessive sweating. The product can also prevent hypokalemia. Budaxiu is a national essential medicine and included in the national medical insurance catalog. It has a sales history of more than 30 years, with high brand recognition and a good reputation. The company is the first in the country to pass the consistency evaluation for potassium chloride extended-release tablets. After being selected in the fifth batch of national centralized drug procurement in 2021, the product's coverage and sales in medical institutions have both increased.
Harbin Gloria Pharmaceuticals (002437.SZ): Currently promoting first and third joint products are cardiovascular and cerebrovascular drugs.
Harbin Gloria Pharmaceuticals (002437.SZ) recently stated during a reception for institutional investors that the company has been cooperating with Daiichi Sankyo since 2015. The two parties have had a good cooperative relationship for nearly 10 years, and the cooperation is stable. Currently, the Daiichi Sankyo products promoted by the company are all cardiovascular and cerebrovascular drugs.
Harbin Gloria Pharmaceuticals (002437.SZ): Holds a market share of over 80% for injectable multivitamins (12) by Pude Pharmaceutical.
On July 5th, 2024, Harbin Gloria Pharmaceuticals (002437.SZ) accepted a specific survey and was asked about the market competitiveness and barriers of multiple vitamin (12) injections. The company replied that currently, there are only two companies selling this product in the market, and the market share of multiple vitamin (12) injections by Pude Pharmaceutical exceeds 80%. The market for this product is large and the difficulty of imitation is high. It is expected that the market structure will be relatively stable in the next 2-3 years.
Harbin Gloria Pharmaceuticals (002437.SZ): PuDe Pharma has signed more than 100 CMO business products in total, and future CMO business will move closer to the research and development end.
On July 5th, Gelonhui reported that Harbin Gloria Pharmaceuticals (002437.SZ) accepted specific inquiries on July 5th, 2024 regarding "What is the business scale of CMO and the layout of CDMO?" The company responded that Pude Pharmaceutical is a well-known injection contract manufacturing organization in the north, and has signed more than 100 CMO businesses of various products. As these products are successively approved, launched, and sold, it is expected to contribute to the revenue and profits of the company. In the future, the company's CMO business will move closer to the R&D end, striving to make better products. The company has partnered with Nanjing BioMap for equity + product cooperation, and has carried out business with other CRO enterprises.
Harbin Gloria Pharmaceuticals' H1 Profit to Soar Up to 360%
No Data